6 / 24
Biomarkers
•
1
st
Line: Not ready for prime time
•
Hyaluronic acid high:
≃
40%
HALO-109-301 trial
PEGPH20 + gemcitabine + nab-paclitaxel
SWOG1313 Phase 2 trial PEGPH20 plus modified FOLFIRINOX: negative results
•
BRCA1&2:
Germinal mutation 3%
BRCAness phenotype – Defects of DNA Repair System 14-24%
1
(PALB, ATM, ATR, etc.)
POLO trial – manteinance olaparib
PARP inhibitor-olaparib & platinum-based therapy?
1
Dreyer et al. Clin Cancer Res 2017